Midatech Pharma PLC
LSE:MTPH
Midatech Pharma PLC
Research & Development
Midatech Pharma PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Midatech Pharma PLC
LSE:MTPH
|
Research & Development
-£4.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$150.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$238.3m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$119m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
-£15.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
£9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Midatech Pharma PLC
Glance View
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 40 full-time employees. The company went IPO on 2014-12-08. The firm has developed three in-house technology platforms, each with its own mechanism to improve delivery of medications to sites of disease. The firm's platform includes Q-Sphera platform, MidaSolve platform and MidaCore platform. Q-Sphera platform is a micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). MidaSolve platform is a nanotechnology used to dissolve insoluble drugs, which can be administered in liquid form directly and locally into tumors. MidaCore platform is a nanotechnology used for targeting medications to sites of disease. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211, MTD214, MTD220, MTX213, MTX214, MTX216, MTX110, MTX110, MTX110 and MTX114.
See Also
What is Midatech Pharma PLC's Research & Development?
Research & Development
-4.7m
GBP
Based on the financial report for Dec 31, 2021, Midatech Pharma PLC's Research & Development amounts to -4.7m GBP.
What is Midatech Pharma PLC's Research & Development growth rate?
Research & Development CAGR 1Y
23%
Over the last year, the Research & Development growth was 23%.
